Novotech Health Holdings appointed Zhang Zidong as Chief Financial Officer

Novotech Health Holdings, Asia's leading biotechnology professional contract research organization (CRO), recently announced the appointment of Zhang Zidong as Chief Financial Officer, effective January 4, 2021. Mr. Zhang will be fully responsible for the company's financial management and will work closely with Novotech Holdings' executive team to help the company grow its business in Asia.Prior to joining Novotech Holdings, Dr. Zhang served as Chief Financial Officer at Shanghai-based Fuhong Hanxuan. Dr. Zhang Zidong, a Hong Kong-listed global biopharmaceutical company, was responsible for the formation and management of the company's finance team during his tenure as Chief Financial Officer and played an integral role in Fuhong Hanxuan's 2019 initial public offering. Prior to that, Dr. Zhang worked as a ubs equity analyst in New York, focusing on the specialty pharmaceutical industry. He also served as a senior consultant in the Healthcare business of the Bayer Group and was engaged in postdoctoral research in diabetes drug development at Boston University School of Medicine. Dr. Zhang holds a Ph.D. in Biochemistry from Boston University, an MBA from Duke University, and a Bachelor of Chemistry degree from Fudan University.Joel Thickins, Chairman of Novotech Holdings and Head of TPG Asia Capital Australia and New Zealand, said: "Mr. Zhang has extensive experience in financial management, capital markets transactions, and healthcare research and consulting, and his unique skills and experience are well in line with the company's future development goals. He will further strengthen Novotech's leadership team and drive the company to expand in Asia. John Moller,chief executive of Novotech Holdings, said: "Mr. Zhang has extensive experience in biotechnology and healthcare, as well as deep financial expertise at UBS and Fuhong Hanxuan. His talents are a valuable asset as the company enters the next phase of business growth. We welcome Mr. Zhang Zidong to Novotech Holdings. Mr , Mr. Zhang Zidong, said, "The biotechnology industry in Asia is still in its infancy and the demand for quality clinical trial services will increase significantly as the industry develops further." I am pleased to join Novotech Holdings and have the privilege of working with such an excellent team of professionals to achieve a strong growth strategy in helping our customers develop the next generation of innovative drugs.About NOVOTECH HEALTH HOLDINGS Novotech Health Holdings ("Novotech Holdings") is Asia's leading biotechnology professional contract research organization (CRO) platform, consisting of a merger of Novotech and PPC Jiasheng Group. Novotech Holdings offers a full range of services, integrated laboratories and phase I facilities for drug development consulting and clinical development services. Novotech Holdings has contributed to the success of more than 3,700 clinical trials. These trials cover all stages and treatment areas. Novotech Holdings has a unique advantage in serving clinical trials for biotechnology customers in Asia and around the world. Novotech Holdings has approximately 1,550 employees and 21 offices in 12 regions, including Greater China, Korea, Southeast Asia, India and ANZ. TPG Asia Capital funds hold a controlling stake in Novotech Holdings.About TPGTPG was founded in 1992 as a leading global alternative asset manager with approximately $85 billion in assets under management. TPG has offices in San Francisco, Fort Worth, Austin, New York, Washington, Beijing, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, Seoul and Singapore. TPG's investment platform covers a wide range of asset classes, including private equity, growth funds, impact investments, real estate and public funds, providing its investors with a wide range of investment products and options, while increasing the value of its invested companies through strict and effective management. (
Novotech Health Holdings
Corporate Website)